Article Text

Download PDFPDF
Letter
Response to imiquimod 5% cream as treatment for condyloma and anal intraepithelial neoplasia in HIV-positive and HIV-negative patients
  1. Chiara Santorelli1,
  2. Cosimo Alex Leo2,
  3. Franco Baldelli1,
  4. Emanuel Cavazzoni1
  1. 1Department of Surgery, University of Perugia, School of Medicine, Perugia, Italy
  2. 2St Mark's Hospital Academic Institute, Harrow, Middlesex, UK
  1. Correspondence to Cosimo Alex Leo, St Mark's Hospital Academic Institute, London North West NHS Trust, 1, Watford Road, Middlesex, Harrow HA1 3UJ, UK; cosimoleo{at}gmail.com

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Treatments for anal intraepithelial neoplasia (AIN) include non-operative options and more invasive treatments, such as wide local excision.1 Unfortunately, recurrence rates remain high regardless of treatment and therefore surveillance is paramount.2 We performed a study of patients who underwent treatment of condyloma and AIN using imiquimod 5% cream and compared outcomes in those patients with and without HIV. We retrospectively reviewed patients who underwent anal cancer screening …

View Full Text

Footnotes

  • Contributors CS collected the patient data and has drawn the study. CAL analysed the data. FB supervised the laboratory testing. EC supervised the study. All authors contributed to the preparation of the manuscript.

  • Competing interests None.

  • Ethics approval Local Institutional Board.

  • Provenance and peer review Not commissioned; internally peer reviewed.